Edwards Lifesciences Corporation logo
EWEdwards Lifesciences Corporation

Debt to Assets Ratio: 5.28%

popular:market cap|pe ratio|revenue|price history|total return

Is the debt to assets ratio high or low?

The debt to assets ratio of 5.28% is 26% below its 5-year average of 7.09%, near the low end of its 5-year range (5.15%–9.55%).

As of Sunday, June 28, 2026. 0.38% above its 12-month average of 5.26%.

Debt/Equity|Total Debt|Total Assets|Interest Coverage|All Metrics
Debt to Assets

EW Debt to Assets Ratio

5.28%

Reported quarterly debt to assets ratio; no daily interpolation.

-40.91% 5Y
EW Debt to Assets Ratio

EW Average Debt to Assets Ratio Chart

EW Debt to Assets Ratio

EW Current vs Average Debt to Assets Ratio Chart

EW Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

5.28%

DEBT TO ASSETS RATIO AVG TTM

5.26%

DEBT TO ASSETS RATIO AVG 3Y

6.26%

DEBT TO ASSETS RATIO AVG 5Y

7.09%

DEBT TO ASSETS RATIO AVG 10Y

10.82%

DEBT TO ASSETS RATIO AVG 15Y

11.75%

DEBT TO ASSETS RATIO AVG 20Y

12.07%

CURRENT VS TTM AVG

+0.38%

CURRENT VS 3Y AVG

-15.71%

CURRENT VS 5Y AVG

-25.60%

CURRENT VS 10Y AVG

-51.24%

CURRENT VS 15Y AVG

-55.09%

CURRENT VS 20Y AVG

-56.29%

EW Competitors' Debt to Assets Ratio

NAMEMARKET CAPDEBT TO ASSETS RATIOTTM3Y5Y
Edwards Lifesciences Corporation (EW)$52.27B5.28%5.26%6.26%7.09%
Cencora, Inc. (COR)vs ›$55.67B0.14%N/AN/AN/A
Cardinal Health, Inc. (CAH)vs ›$55.72B0.18%N/AN/AN/A
Becton, Dickinson and Company (BDX)vs ›$56.49B0.35%N/AN/AN/A
Humana Inc. (HUM)vs ›$46.08B0.27%N/AN/AN/A
IDEXX Laboratories, Inc. (IDXX)vs ›$43.50B0.32%N/AN/AN/A
Regeneron Pharmaceuticals, Inc. (REGN)vs ›$65.20B0.07%N/AN/AN/A
Boston Scientific Corporation (BSX)vs ›$65.74B0.28%N/AN/AN/A
Agilent Technologies, Inc. (A)vs ›$38.41B0.26%N/AN/AN/A
Medline Inc. (MDLN)vs ›$32.87B0.33%N/AN/AN/A

Leverage Ratios Comparison

Debt/Assets

5.3%

Debt/Equity

0.07

Current Ratio

3.72

Interest Coverage

N/A

Formula: Debt/Assets = Total Debt / Total Assets × 100

Debt/Assets vs Debt/Equity:

  • Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
  • Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
  • Both measure leverage but from different perspectives

Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.

Debt to Assets Ratio Formula & Definition

Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Edwards Lifesciences Corporation (EW)?
The debt to assets ratio for EW stock is 5.28%.
Is Edwards Lifesciences Corporation's debt to assets ratio high or low?
The debt to assets ratio of 5.28% is 26% below its 5-year average of 7.09%, near the low end of its 5-year range (5.15%–9.55%).
What is the TTM average debt to assets ratio for Edwards Lifesciences Corporation (EW)?
The TTM average debt to assets ratio for EW stock is 5.26%.
What is the 3Y average debt to assets ratio for Edwards Lifesciences Corporation (EW)?
The 3Y average debt to assets ratio for EW stock is 6.26%.
What is the 5Y average debt to assets ratio for Edwards Lifesciences Corporation (EW)?
The 5Y average debt to assets ratio for EW stock is 7.09%.
What is the 10Y average debt to assets ratio for Edwards Lifesciences Corporation (EW)?
The 10Y average debt to assets ratio for EW stock is 10.82%.
What is the 15Y average debt to assets ratio for Edwards Lifesciences Corporation (EW)?
The 15Y average debt to assets ratio for EW stock is 11.75%.
What is the 20Y average debt to assets ratio for Edwards Lifesciences Corporation (EW)?
The 20Y average debt to assets ratio for EW stock is 12.07%.

EW Debt to Assets Ratio History

DATEDEBT TO ASSETS RATIO
2026-03-315.28%
2025-12-315.15%
2025-09-305.28%
2025-06-305.21%
2025-03-315.37%
2024-12-315.36%
2024-09-305.45%
2024-06-306.86%
2024-03-317.18%
2023-12-317.32%
2023-09-307.38%
2023-06-307.60%
2023-03-317.95%
2022-12-318.34%
2022-09-307.95%
2022-06-308.10%
2022-03-318.17%
2021-12-318.12%
2021-09-308.38%
2021-06-308.93%
2021-03-319.55%
2020-12-319.60%
2020-09-3010.15%
2020-06-3010.66%
2020-03-3111.11%
2019-12-3110.46%
2019-09-3011.24%
2019-06-3011.99%
2019-03-3112.18%
2018-12-3111.15%
2018-09-3020.03%
2018-06-3020.98%
2018-03-3118.10%
2017-12-3118.19%
2017-09-3018.84%
2017-06-3019.79%
2017-03-3117.74%
2016-12-3118.23%
2016-09-3013.84%
2016-06-3014.87%
2016-03-3115.63%
2015-12-3114.70%
2015-09-3015.60%
2015-06-3016.64%
2015-03-3117.28%
2014-12-3116.97%
2014-09-3018.21%
2014-06-3017.98%
2014-03-3127.36%
2013-12-3121.77%
2013-09-3021.03%
2013-06-309.71%
2013-03-318.39%
2012-12-318.52%
2012-09-307.99%
2012-06-308.92%
2012-03-318.95%
2011-12-317.59%
2011-09-308.83%
2011-06-308.73%
2011-03-317.74%
2010-12-312.37%
2010-09-305.83%
2010-06-3010.81%
2010-03-318.06%
2009-12-315.59%
2009-09-306.44%
2009-06-307.77%
2009-03-319.05%
2008-12-3112.53%
2008-09-3014.68%
2008-06-3010.51%
2008-03-3116.25%
2007-12-3115.74%
2007-09-3016.25%
2007-06-3016.58%
2007-03-3117.97%
2006-12-3118.92%
2006-09-3020.40%
2006-06-3022.20%
2006-03-3123.31%
2005-12-3125.72%
2005-09-3021.97%
2005-06-3023.43%
2005-03-3124.56%
2004-12-3124.00%
2004-09-3025.11%
2004-06-3028.71%
2004-03-3130.30%
2003-12-3123.22%
2003-09-3027.37%
2003-06-3028.46%
2003-03-3126.73%
2002-12-3124.35%
2002-09-3030.48%
2002-06-3030.26%

Related Metrics

Debt/EquityTotal DebtTotal AssetsInterest CoverageAll Metrics

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Irvine, CA
15,800 employees
www.edwards.com
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Bernard J. Zovighian
View full financials